Pharma Disease Insights: Multiple Myeloma (PowerPoint PPTX Slide Deck)

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market